Show simple item record

dc.contributor.authorRodríguez Gascón, Alicia
dc.contributor.authorSolinís Aspiazu, María Ángeles ORCID
dc.contributor.authorIsla Ruiz, Arantxazu ORCID
dc.date.accessioned2021-07-09T16:02:13Z
dc.date.available2021-07-09T16:02:13Z
dc.date.issued2021-06-03
dc.identifier.citationPharmaceutics 13(6) : (2021) // Article ID 833es_ES
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10810/52262
dc.description.abstractPharmacokinetic/pharmacodynamic (PK/PD) analysis has proved to be very useful to establish rational dosage regimens of antimicrobial agents in human and veterinary medicine. Actually, PK/PD studies are included in the European Medicines Agency (EMA) guidelines for the evaluation of medicinal products. The PK/PD approach implies the use of in vitro, ex vivo, and in vivo models, as well as mathematical models to describe the relationship between the kinetics and the dynamic to determine the optimal dosing regimens of antimicrobials, but also to establish susceptibility breakpoints, and prevention of resistance. The final goal is to optimize therapy in order to maximize efficacy and minimize side effects and emergence of resistance. In this review, we revise the PK/PD principles and the models to investigate the relationship between the PK and the PD of antibiotics. Additionally, we highlight the outstanding role of the PK/PD analysis at different levels, from the development and evaluation of new antibiotics to the optimization of the dosage regimens of currently available drugs, both for human and animal use.es_ES
dc.description.sponsorshipThis research was funded by the Department of Education of the Basque Government (PIBA 2019-57) and by the University of the Basque Country UPV/EHU (GIU 17/32).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectantibiotices_ES
dc.subjectpharmacokineticses_ES
dc.subjectpharmacodynamicses_ES
dc.subjectantimicrobial resistancees_ES
dc.titleThe Role of PK/PD Analysis in the Development and Evaluation of Antimicrobialses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2021-06-24T14:11:38Z
dc.rights.holder© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/6/833es_ES
dc.identifier.doi10.3390/pharmaceutics13060833
dc.departamentoesFarmacia y ciencias de los alimentos
dc.departamentoeuFarmazia eta elikagaien zientziak


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).